[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-system\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-system":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,79,114,142,165,188,223,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100464991","sex-differential-host-microbiome-cvd-risk---a-longitudinal-cohort-approach-100464991",false,"NCT05334888","Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach","Sex Hormone-specific Cardiovascular Risks in the Gut Microbiome-host Axis - A Longitudinal Cohort Study.","XCVD","Inclusion Criteria:\n\n* Age 18-50\n* Language requirements: German, English\n* Previous gender hormone replacement therapy (HRT).\n* Ability to give consent and written consent to participate.\n* Health insurance (for clarification of incidental findings)\n\nExclusion Criteria:\n\n* Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.\n* Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.","ALL","18 Years","50 Years",{"count":21,"type":22},200,"ESTIMATED","2 Years","OBSERVATIONAL","The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for five years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.",[27,28,29,30],"Transgender","Gut Microbiome","Immune System","Cardiovascular Risk Factors",[32],"Transgender Medicine","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2022-08-29",{"date":41,"type":22},"2030-12-31",{"name":43,"class":44},"Charite University, Berlin, Germany","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100489055","immune-profile-analysis-and-biomarker-identification-in-women-with-repeated-implantation-failure-or-unexplained-recurrent-spontaneous-miscarriage-100489055","NCT05648136","Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage","ERIM","Inclusion Criteria:\n\n* For patients :\n* Women aged 18 to 39 years\n* women with a history of RIF or unexplained RM\n* women with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)\n* women with a basal FSH level \\\u003C10IU\u002Fl and AMH level \\>1.5ng\u002Fml\n* women with a regular menstrual cycle of 30+\u002F-5 days\n* women receiving a new cycle of in vitro fertilization (IVF) +\u002F- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +\u002F-ICSI for patients in the RM group\n* women received written and oral information and signed an informed consent\n\nFor control groups:\n\n* Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)\n* Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+\u002F-ICSI procedure for secondary infertility\n* Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication.\n\nExclusion Criteria:\n\n* Ongoing pelvic and\u002For systemic infection\n* Chronic infectious endometritis\n* Active neoplasia\n* Autoimmune and autoinflammatory disease\n* Celiac disease\n* Thrombophilia (including positive anti-phospholipid antibodies)\n* Endocrine pathology (including dysthyroidism and diabetes)\n* Endometriosis\n* Polycystic ovary syndrome and ovulatory disorders\n* Premature ovarian failure\n* IVF by oocyte donation\n* Tubal obstructions or lesions, uterine and cervical anomalies\n* Partners with extreme oligoastheno-spermia and\u002For sperm DNA fragmentation \\>30\n* Sperm donations\n* Patients unable to give informed consent",true,"FEMALE","39 Years",{"count":57,"type":22},150,"INTERVENTIONAL",[60],"NA","Implantation is a determining step in human reproduction which requires the transition from a pro-inflammatory state to an anti-inflammatory state allowing the implantation of a competent embryo within a receptive endometrium, and then the maternal immunotolerance towards the alloantigenic fetus. Repeat implantation failures (RIFs), that refers to the fail to achieve a clinical pregnancy after the transfer of at least 3-4 good quality embryos or two blastocysts, and unexplained recurrent spontaneous miscarriage (RM) (≥2-3) could be related in some patients to immune imbalances characterized by an excessive and prolonged inflammatory response and\u002For a defect of anti-inflammatory regulation. In this context, several therapies have been evaluated in patients with RIFs or RMs in order to restore the immune balance, with heterogeneous results. No serum biomarker assay has been routinely approved to identify patients with immune imbalances that may explain repeated pregnancy failures and to predict the success of the subsequent IVF\u002FICSI cycle. The immunological analysis on peripheral blood will be based on the determination of the proportions of immune subpopulations (e.g. CD4+ et CD8+, TH1, TH2, TH17, Treg, ILC 1, ILC2, and ILC3) on the one hand and the circulating level of plasma cytokines on the other hand.",[63,64,29],"Repeated Embryo Implantation Failure","Recurrent Miscarriage",[66,67,68,69],"repeated embryo implantation failure","recurrent spontaneous miscarriage","immunological analysis","immune system","2026-06-10",{"date":72,"type":37},"2026-06-11",{"date":74,"type":37},"2024-08-26",{"date":76,"type":22},"2026-08",{"name":78,"class":44},"Centre Hospitalier Universitaire, Amiens",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":54,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":58,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100637766","effects-of-moderate-intensity-interval-aerobic-exercise-miiae-on-inflammatory-immune-metabolic-physical-fitness-and-quality-of-life-parameters-in-breast-cancer-patients-undergoing-radiotherapy-100637766","NCT07583719","Effects of Moderate-intensity Interval Aerobic Exercise (MIIAE) on Inflammatory, Immune, Metabolic, Physical Fitness, and Quality of Life Parameters in Breast Cancer Patients Undergoing Radiotherapy.","Inclusion Criteria:\n\n* Women aged between 20 and 65 years.\n* Clinical diagnosis of breast cancer (Stage I-III).\n* Patients who have undergone lumpectomy or mastectomy.\n* Scheduled to start radiotherapy treatment.\n* Sedentary lifestyle according to international physical activity guidelines.\n* Ability to understand and follow instructions.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of infectious disease.\n* Cardiovascular or respiratory disease.\n* Metastatic disease.\n* Uncontrolled diabetes mellitus.\n* Neuropathy.\n* Physically active individuals meeting WHO physical activity recommendations.\n* Participation in an exercise intervention program within the last 3 months.\n* Any condition that, in the opinion of the research team, may compromise safety or participation.","20 Years","65 Years",{"count":88,"type":22},40,[60],"Breast cancer and its treatment with radiotherapy may be associated with systemic inflammatory, hematological, cardiac, body composition, functional and quality-of-life alterations. Exercise has emerged as a non-pharmacological strategy with potential benefits during oncological treatment; however, further evidence is needed regarding the effects of supervised moderate-intensity interval aerobic exercise during radiotherapy.\n\nThis randomized controlled trial aims to evaluate the effects of a supervised moderate-intensity interval aerobic exercise programme on systemic inflammatory and immune-derived hematological indices, cardiac biomarkers, body composition, muscle strength, lower-limb power, sleep quality and breast cancer-specific quality of life in women with breast cancer undergoing radiotherapy.\n\nParticipants will be allocated to either an experimental group performing supervised moderate-intensity interval aerobic exercise during radiotherapy or to a control group receiving usual care without structured exercise during the study period. Outcomes will be assessed at baseline and after completion of the intervention period.",[92,93,29,94,95],"Radiotherapy","Inflamation","Physical Fitness","Breast Cancer",[97,98,99,100,101,95,102,103],"Interval Training","Inflammation","Body Composition","Quality of Life","Immune function","Sleep","oncology rehabilitation","NOT_YET_RECRUITING","2026-05-06",{"date":107,"type":37},"2026-05-13",{"date":109,"type":22},"2026-06-01",{"date":111,"type":22},"2026-12-31",{"name":113,"class":44},"Universidad Francisco de Vitoria",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":53,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":58,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100624426","design-and-development-of-a-functional-plant-based-beverage-to-improve-nutritional-status-and-immunity-for-the-early-elderly-people-to-get-well-healthy-ageing-100624426","NCT07409480","Design and Development of a Functional Plant-based Beverage to Improve Nutritional Status and Immunity for the Early Elderly People to Get Well-healthy Ageing","Immugold","Inclusion Criteria:\n\n* Men or women ≥60 years old \\\u003C80 years old.\n* Written informed consent provided before the initial screening visit.\n\nExclusion Criteria:\n\n* Hypoglycaemic treatment or type 1 and type 2 diabetes mellitus diagnosed.\n* Anaemia (haemoglobin ≤13 g\u002FdL in men and ≤12 g\u002FdL in women).\n* Intestinal malabsorption diseases, such as chron disease, colitis ulcerous, and irritable bowel syndrome.\n* Immune pathology or depressed immune system.\n* Use of antioxidants or nutritional supplements.\n* Known allergy or hypersensitivity to oat, coconut, or any formulation ingredient.\n* Renal diseases or history of hypercalcemia, sarcoidosis, or hyperparathyroidism.\n* History of inborn errors of metabolism affecting branched-chain amino acid metabolism.\n* Chronic alcoholism.\n* Current or past participation in a clinical trial or consumption of a research product in the 30 days before inclusion in the study.\n* Failure to follow the study guidelines.","60 Years","80 Years",{"count":124,"type":22},70,[60],"In 2018, for the first time, the number of people aged 65 and over exceeded the number of children under the age of 5. A rise in ageing societies is coming, and new efforts are needed to ensure that this increase in life expectancy is accompanied by years of health and a good quality of life. The new focus for our ageing society will be an extended healthspan, the period of life spent in good health. This is an important shift, as population ageing is a defining global trend of our time. By 2030, 1 in 6 people in the world will be 60 years and older, according to the World Health Organization. In this sense, the imperative to maintain the health and activity levels of the senior demographic has never been more critical. Advances in healthcare, science, and technology have contributed to increased longevity, yet this does not always equate to improved health.\n\nThe prevalence of malnutrition or the risk thereof among the elderly living independently in Europe ranges from 13.5% to 29.7%, highlighting a pressing need for nutritional intervention. Addressing this, the pursuit of innovative nutritional sources and the creation of new food products enriched with these sources are essential to bridging the nutritional gap, ensuring healthier aging prospects for this population. The formulation of food products tailored to the elderly must consider their unique nutritional requirements, particularly concerning protein and micronutrient intake. Recent advances in food technology facilitate the development of plant-based beverages that are palatable, nutritionally adequate, and accessible. Moreover, the growing market share of plant-based non-dairy beverages provides a promising alternative, offering opportunities to deliver bioactive compounds with health-promoting properties, appealing to health-conscious and lactose-intolerant consumers.\n\nGiven the nutritional challenges and health risks faced by the aging population, particularly in relation to protein intake and malnutrition, another critical aspect that warrants attention is the immune system's health through diet. The immune system, which naturally weakens with age, plays a crucial role in the elderly's ability to resist infections and recover from illnesses. Research highlights the impact of not only macronutrients but micronutrients such as vitamins D, C, E, and zinc on enhancing immune responses, suggesting that diets rich in these nutrients can significantly benefit immune health in older adults. Strengthening the immune system through diet becomes even more pertinent considering the increased vulnerability of the elderly to infectious diseases, including respiratory infections like influenza and pneumonia, which are leading causes of morbidity and mortality in this population. Developing food products that are not only nutritionally adequate but also tailored to support immune function could provide a dual benefit: improving general health and enhancing the body's defence mechanisms.\n\nThe present research project is structured into three coordinated phases and is enabled by the multidisciplinary nature of the IMMUGOLD consortium. In the first phase, AZTI conducted an extensive literature and technical review to identify functional ingredients capable of supporting immune function while remaining compatible with the technological, sensory, and stability requirements of a plant-based beverage. This process identified vitamin D, zinc, FOS, and L-leucine as the most suitable bioactive components, considering bioavailability, processing stability, and expected physiological effects. In the second phase, COSTA carried out the development and reformulation of the oat-based beverage to ensure nutritional adequacy, ingredient stability under thermal treatment, and organoleptic acceptability for older consumers. Finally, the third phase involves a clinical study, to be executed by Universitat Rovira i Virgili (URV), which aims to evaluate the effects of the newly developed fortified beverage on markers of immune function and systemic inflammation in community-dwelling older adults, with secondary outcomes including nutritional status and other health-related parameters relevant to ageing.\n\nThe multidisciplinary expertise of the consortium, including computational modelling, ingredient research, nutrition, food product development, and clinical epidemiology, ensures the feasibility of the project and the successful achievement of its objectives: AZTI provides evidence-based solutions for functional ingredients; COSTA develops innovative plant-based beverages; and URV contributes extensive experience in designing and implementing nutritional programs and clinical studies.",[98,29],[129,69,130,131,132],"inflammation","nutritional status","sarcopenia","cognitive impairment","2026-02-13",{"date":135,"type":37},"2026-02-18",{"date":137,"type":22},"2026-02-09",{"date":139,"type":22},"2027-05-31",{"name":141,"class":44},"University Rovira i Virgili",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":149,"targetDuration":4,"studyType":58,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100594493","phase-1-a-first-in-human-phase-i-trial-of-ox118-in-healthy-volunteers-100594493","NCT07020156","A First-in-Human Phase I Trial of OX118 in Healthy Volunteers","A First in Human Phase 1 Trial of OX118 in Healthy Volunteers","Inclusion Criteria:\n\n1. Willing and able to give written informed consent for participation in the trial.\n2. Healthy male or female participant aged 18 to 60 years, inclusive.\n3. Weighs ≥ 50 and ≤ 100 kg and has a body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg\u002Fm2 at the time of the screening visit.\n4. Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG and laboratory values at the time of the screening visit, as judged by the Investigator.\n\n   (Discussion is encouraged between the Investigator and the Sponsor medical representative regarding the clinical relevance of any abnormal laboratory value during the pre-dose period.)\n5. Women of childbearing potential (WOCBP) must practice abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the participant) or must agree to use a highly effective method of contraception with a failure rate of \\\u003C1 % to prevent pregnancy from at least 2 weeks prior to the administration of IMP to 3.5 months (15 weeks) after the last administration of IMP. In addition, any male partner of a female participant must, unless he has undergone vasectomy, agree to use a condom from the administration of IMP until 3.5 months (15 weeks) after the last administration of IMP.\n\nThe following are considered highly effective methods of contraception:\n\n* combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal),\n* progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable),\n* intra-uterine device \\[IUD\\]or intra-uterine hormone-releasing system \\[IUS\\]). WOCBP must refrain from donating eggs from the first IMP administration until 6 months after the last IMP administration. WOCBP with an exclusive male partner who has undergone vasectomy may choose not to use contraceptives.\n\nWomen of non-childbearing potential are pre-menopausal females who have undergone any of the following surgical procedures; hysterectomy, bilateral salpingectomy or bilateral oophorectomy, or who are post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \\[FSH\\] \\>25 IU\u002FL is confirmatory).\n\nMale participants must be willing to use a condom or be vasectomised or practice sexual abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the participant) to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the first administration of IMP until 6 months after the last administration of IMP. Any female partner of a non-vasectomised male participant who is of childbearing potential must use contraceptive methods with a failure rate of \\\u003C 1% to prevent pregnancy (see above) from at least 2 weeks prior to the first administration of IMP to 3.5 months (15 weeks) after the last administration of IMP\n\nExclusion Criteria:\n\n1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial or influence the results or the participant's ability to participate in the trial.\n2. Any clinically significant illness, medical\u002Fsurgical procedure or trauma within 4 weeks of the administration of IMP.\n3. Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.\n4. Any planned major surgery within the duration of the trial.\n5. Participants who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.\n6. Any positive result at the screening visit for serum hepatitis B surface antigen, hepatitis C antibodies and\u002For human immunodeficiency virus (HIV).\n7. After 10 minutes supine rest at the screening visit, any vital signs values outside the following ranges:\n\n   * Systolic BP: \\\u003C90 or ≥140 mmHg, or\n   * Diastolic BP \\\u003C50 or ≥90 mmHg, or\n   * Pulse \\\u003C40 or ≥90 bpm\n8. Prolonged QTcF (\\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the screening visit, as judged by the Investigator.\n9. History of severe allergy\u002Fhypersensitivity or ongoing allergy\u002Fhypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to OX118.\n10. Regular use of any prescribed or non-prescribed medications, including antacids, analgesics, herbal remedies, vitamins and minerals, within 2 weeks prior to the administration of IMP, except occasional intake of paracetamol (maximum 2000 mg\u002Fday and not exceeding 3000 mg\u002Fweek), as well as nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.\n11. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. Participants who consented and screened but were not dosed in previous Phase I trials are not to be excluded.\n12. Current smokers or users of nicotine products (e.g., smoking, snuffing, chewing tobacco) corresponding to ≥ 5 cigarettes per day.\n13. Positive screening result for drugs of abuse or alcohol at the screening visit or on admission to the trial site prior to the administration of the IMP. (Positive results that are expected given the participant's medical history and prescribed medications can be disregarded as judged by the Investigator.)\n14. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.\n15. Presence or history of drug abuse, as judged by the Investigator.\n16. History of, or current use of anabolic steroids, as judged by the Investigator.\n17. Excessive caffeine consumption defined by a daily intake of \\> 5 cups (1 cup = approximately 240 mL) of caffeine-containing beverages, as judged by the Investigator.\n18. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening.\n19. The Investigator considers the participant unlikely to comply with trial procedures, restrictions and requirements",{"count":150,"type":22},32,[152],"PHASE1","This is a first-in-human, phase 1 study of OX118 in healthy volunteers, designed to investigate the safety and tolerability of OX118, as well as its pharmacokinetics (the drug's concentration in the blood and excretion from the body).\n\nThe study will include a total of 32 participants: healthy men and women aged 18-60 years with a body mass index (BMI) between ≥18.5 and ≤30.0.The study is divided into five cohorts where OX118 will be given as a single dose intravenously (into the blood).\n\nThe study consists of 7 clinic visits taking place over a period of approximately 77 days (including a 28-day screening period). During the study, subjects will be given the study drug (OX118) or placebo. Both the study drug and the placebo will be given as a single dose as an intravenous (directly into the blood) infusion. A pre-arranged schedule will determine whether subjects will receive the study drug or the placebo.",[29],"2025-06-05",{"date":157,"type":37},"2025-06-13",{"date":159,"type":37},"2025-04-03",{"date":161,"type":22},"2025-10-29",{"name":163,"class":164},"Oxion Biologics AB","INDUSTRY",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":53,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100524485","immunoprofilling-of-peripheral-blood-mononuclear-cells-in-children-with-attention-deficithyperactivity-disorder-100524485","NCT06109337","Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit\u002FHyperactivity Disorder","Inclusion Criteria:\n\nClinical diagnosis of ADHD； Children with an IQ≥70； Both parents are Han； Agree to take venous blood with informed consent；\n\nExclusion Criteria:\n\nSchizophrenia, mood disorder, autism, mental retardation； Obvious physical and nervous system abnormalities；","6 Years","12 Years",{"count":174,"type":22},100,"The goal of this observational study is to learn about The immune cell landscape of peripheral blood mononuclear cells in children with ADHD compared to typically developing controls. The main question it aims to answer are: 1.Testing the differences in immune cell subpopulations, protein expression and signaling pathways and cell subsets between two groups 2. Exploring the correlations between immune function in PBMC and resting-state brain functional networks in children with ADHD.\n\nParticipants will be taken peripheral blood about 5 ml , cognitive assessment including Intelligence testing, Stroop color-word test and Trail making test, clinical interview and brain structural and functional MRI.",[177,29,178],"ADHD","Clinical Syndrome","2025-03-27",{"date":181,"type":37},"2025-04-01",{"date":183,"type":37},"2023-12-04",{"date":185,"type":22},"2027-12",{"name":187,"class":44},"First Affiliated Hospital of Zhejiang University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":199,"conditions":200,"keywords":206,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100554812","impact-of-uterine-immune-profiling-and-personalized-treatments-in-patients-receiving-a-single-blastocyst-a-matched-controlled-study-100554812","NCT06503952","Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst: a Matched Controlled Study","UTIMPROSET","For case: Uterine immune profiling followed by a Day-5 fresh SET or day-5 or Day-6 freeze-thawed SET within the nine months following the uterine immune profiling between January 2020 and June 2023.\n\nWill be excluded patients with no SET day-5, with uterine immune profiling more than nine months before, or with no matching pair For control: Blastocyst SET without uterine immune profiling within the year prior the embryo transfer matched to the case group between January 2018 on June 2023\n\n* maternal age (+\u002F-1 year) and\n* the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and\n* the same type of transfer (IVF, ICSI, frozen transfer) and\n* the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).","41 Years",{"count":198,"type":22},340,"A recent randomised controlled trial and previous large cohort studies have shown that the uterine immune environment is a crucial element in improving the performance of Assisted Reproductive therapy (ART). As previous studies mixed Day-3, Day-5, single or doble embryo transfer, the clear influence of the endometrial environment on the embryo itself and its type of transfer (fresh or freeze thawed) need further investigation.\n\nTo complement previous studies, the present matched- pair study aims to select the population who exclusively received a single Day-5 embryo transfer (SET) and benefitted of a uterine immune profiling between 1 January 2020 and 30 June 2023 before the SET Day-5.\n\nThis population will be matched to a population. who did not have uterine immune profiling in the nine months prior to the single Day 5 embryo transfer between 2018 and 2023.\n\nThe matching criteria are the maternal age (+\u002F-1 year), the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and the same type of transfer (IVF, ICSI, frozen transfer) and the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).\n\nThe primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations",[201,202,203,204,205,29],"Infertility","Success Rate of Assisted Reproductive Therapy","Single Embryo Transfer","Pregnancy Outcomes","Immunological Tolerance",[207,208,209,210,211,212],"infertility","success rate of assisted reproductibve therapy","Single embryo transfer","uterine immune profiling","personalized care","Live birth rate","2024-12-20",{"date":215,"type":37},"2024-12-27",{"date":217,"type":22},"2025-01-15",{"date":219,"type":22},"2025-05-30",{"name":221,"class":44},"Matricelab Innove",2,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":45},"100552247","the-lymphocytic-infiltrate-of-lung-tumors-100552247","NCT06470607","The Lymphocytic Infiltrate of Lung Tumors.","Biological Observational Monocentric Study Aimed at Analyzing the Lymphocytic Infiltrate of Lung Tumors","TREGILC","Inclusion Criteria:\n\n* Ability to provide informed consent;\n* Men and women over the age of 18;\n* Patients candidates for surgical treatment diagnosed with thoracic tumors\n\nExclusion Criteria:\n\n* Previous chemotherapy for any cancer within the last 6 months;\n* Pregnant and\u002For breastfeeding women;\n* Immunosuppressive state (states of immunosuppression or ongoing immunosuppressive\u002Fimmunomodulatory treatments)",{"count":124,"type":22},"The study is configured as a monocentric observational transversal biological study.\n\nThe main objective of the study is the reconstruction of the molecular organization of tumors of the thoracic cavity, in particular non-small cell lung cancer (NSCLC).\n\nThe study involves the collection of clinical data and biological material (blood and tumor tissue) from 70 subjects diagnosed with thoracic tumors.",[234,29],"Lung Cancer",[236,237,238],"thoracic tumors","Immune checkpoints","lymphocytes","2024-11-26",{"date":241,"type":37},"2024-11-29",{"date":243,"type":37},"2023-01-20",{"date":245,"type":22},"2028-01-31",{"name":247,"class":44},"Scientific Institute San Raffaele",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":53,"sex":54,"minAge":18,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":58,"phases":259,"briefSummary":260,"conditions":261,"keywords":267,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":45},"100568593","the-effects-of-night-shift-work-on-health-across-the-menstrual-cycle-100568593","NCT06683248","The Effects of Night Shift Work on Health Across the Menstrual Cycle","The Effects of Night Shift Work on Health Across the Menstrual Cycle: a Pilot Study","MENSLEEP","Inclusion Criteria:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives\n* Chronic disease\n* Regular use of nicotine\n* Use of medication\n* Consumes excessive amounts of alcohol or coffee","35 Years",{"count":258,"type":22},60,[60],"The study aims to investigate the effects of sleep deprivation on women's health across different phases of the menstrual cycle.",[262,263,264,265,266,29],"Sleep Deprivation","Menstrual Cycle","Brain Health","Metabolism","Microbiota",[268],"Estrogen","2024-11-11",{"date":271,"type":37},"2024-11-14",{"date":273,"type":37},"2022-04-25",{"date":275,"type":22},"2025-12-31",{"name":277,"class":44},"Uppsala University"]